Clinical and experimental evidence for prevention of acute renal failure induced by radiographic contrast media

Journal of Pharmacological Sciences

Volumn 97, Issue 4, 2005, Pages 473-488

  Itoh, Yoshinori ^a   Yano, Takahisa ^a   Sendo, Toshiaki ^a   Oishi, Ryozo ^a  

^a KYUSHU UNIVERSITY HOSPITAL   (Japan)

Author keywords

Apoptosis of renal tubular cells; Decrease in renal blood flow; Oxidative stress; Prophylaxis; Radiocontrast nephropathy

Indexed keywords

3 (2 CARBOXYMETHOXY 4 METHOXYPHENYL) 1 (3,4 METHYLENEDIOXYPHENYL) 5 PROPOXY 2 INDANCARBOXYLIC ACID; 5 DIMETHYLAMINO N (3,4 DIMETHYL 5 ISOXAZOLYL) 1 NAPHTHALENESULFONAMIDE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; ACETYLCYSTEINE; ALLOPURINOL; AMINOPHYLLINE; AMLODIPINE; ANARITIDE; ASCORBIC ACID; ATRASENTAN; ATRIAL NATRIURETIC FACTOR; BERAPROST; BICARBONATE; BUCLADESINE; CALCIUM CHANNEL BLOCKING AGENT; CASPASE; CONTRAST MEDIUM; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); DIATRIZOATE; DILTIAZEM; DOPAMINE; DOPAMINE 1 RECEPTOR STIMULATING AGENT; ENDOTHELIN; ENDOTHELIN RECEPTOR ANTAGONIST; FELODIPINE; FENOLDOPAM; FUROSEMIDE; HISTAMINE; HYPOXANTHINE; INDOMETACIN; IODINATED CONTRAST MEDIUM; IODIXANOL; IOHEXOL; IOMEPROL; IONIC CONTRAST MEDIUM; IOPAMIDOL; IOPROMIDE; IOTALAMIC ACID; IOTROLAN; IOVERSOL; IOXAGLIC ACID; MANNITOL; MISOPROSTOL; N ACETYL BETA GLUCOSAMINIDASE; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; N(G) NITROARGININE METHYL ESTER; NITRENDIPINE; NONIONIC CONTRAST MEDIUM; PROSTACYCLIN; PROSTAGLANDIN E1; PROTEIN INHIBITOR; SH 6; SODIUM CHLORIDE; THEOPHYLLINE; TRYPTASE; UNCLASSIFIED DRUG; WORTMANNIN;

ACUTE KIDNEY FAILURE; APOPTOSIS; ARTERIAL OXYGEN TENSION; CELL PROTECTION; CELL VIABILITY; CLINICAL TRIAL; DETERIORATION; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG METABOLISM; HEMODIALYSIS; HEMOFILTRATION; HUMAN; HYDRATION; HYPERSENSITIVITY; ISCHEMIA; KIDNEY BLOOD FLOW; KIDNEY CIRCULATION; KIDNEY DISEASE; KIDNEY ISCHEMIA; KIDNEY TUBULE CELL; META ANALYSIS; MORBIDITY; MORTALITY; NEPHROTOXICITY; NONHUMAN; OLIGURIA; OSMOLALITY; OXIDATIVE STRESS; PATHOGENESIS; PERCUTANEOUS CORONARY INTERVENTION; PHYSICAL CHEMISTRY; PROPHYLAXIS; RADIODIAGNOSIS; RASH; REVIEW; RISK FACTOR; SHOCK; SIDE EFFECT; TREATMENT FAILURE; URTICARIA;

EID: 18244379041     PISSN: 13478613     EISSN: None     Source Type: Journal    
DOI: 10.1254/jphs.CRJ05002X     Document Type: Review

References (133)

1. Ozono Y, Maeda T, Matsushita T, Miyazaki M. Drug induced nephropathy. Nippon Rinsho. 2002;60:493-500. (text in Japanese)
2. Briguori C, Tavano D, Colombo A. Contrast agent-associated nephrotoxicity. Prog Cardiovasc Dis. 2003;45:493-503.
3. Dangas G, Iakovou I, Nikolsky E, Aymong ED, Mintz GS, Kipshidze NN, et al. Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. Am J Cardiol. 2005;95:13-19.
4. Andersen KJ, Christensen EI, Vik H. Effects of iodinated x-ray contrast media on renal epithelial cells in culture. Invest Radiol. 1994;29:955-962.
5. Hardiek K, Katholi RE, Ramkumar V, Deitrick C. Proximal tubule cell response to radiographic contrast media. Am J Physiol Renal Physiol. 2001;280:F61-F70.
6. Hizoh I, Haller C. Radiocontrast-induced renal tubular cell apoptosis: hypertonic versus oxidative stress. Invest Radiol. 2002;37:428-434.
7. Zager RA, Johnson AC, Hanson SY. Radiographic contrast media-induced tubular injury: evaluation of oxidant stress and plasma membrane integrity. Kidney Int. 2003;64:128-139.
8. Liss P, Nygren A, Hansell P. Hypoperfusion in the renal outer medulla after injection of contrast media in rats. Acta Radiol. 1999;40:521-527.
9. Lancelot E, Idee JM, Couturier V, Vazin V, Corot C. Influence of the viscosity of iodixanol on medullary and cortical blood flow in the rat kidney: a potential cause of nephrotoxicity. J Appl Toxicol. 1999;19:341-346.
10. Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic contrast agent-induced reductions in renal function by acetylcysteine. N Engl J Med. 2000;343:180-184.
11. Pannu N, Manns B, Lee H, Tonelli M. Systematic review of the impact of N-acetylcysteine on contrast nephropathy. Kidney Int. 2004;65:1366-1374.
12. Spargias K, Alexopoulos E, Kyrzopoulos S, Iacovis P, Greenwood DC, Manginas A, et al. Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation. 2004;110:2837-2842.
13. Morcos SK, Thomsen HS. European Society of Urogenital Radiology guidelines on administering contrast media. Abdom Imaging. 2003;28:187-190.
14. Meyrier A. Nephrotoxicity of iodine contrast media. Ann Radiol (Paris). 1994;37:286-295.
15. Taliercio CP, Vlietstra RE, Fisher LD, Burnett JC. Risks for renal dysfunction with cardiac angiography. Ann Intern Med. 1986;104:501-504.
16. Rich MW, Crecelius CA. Incidence, risk factors, and clinical course of acute renal insufficiency after cardiac catheterization in patients 70 years of age or older. A prospective study. Arch Intern Med. 1990;150:1237-1242.
17. Gussenhoven MJ, Ravensbergen J, van Bockel JH, Feuth JD, Aarts JC. Renal dysfunction after angiography; a risk factor analysis in patients with peripheral vascular disease. J Cardiovasc Surg (Torino). 1991;32:81-86.
18. Porter GA. Contrast-associated nephropathy: presentation, pathophysiology and management. Miner Electrolyte Metab. 1994;20:232-243.
19. Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation. 2002;105:2259-2264.
20. Cigarroa RG, Lange RA, Williams RH, Hillis LD. Dosing of contrast material to prevent contrast nephropathy in patients with renal disease. Am J Med. 1989;86:649-652.
21. Katayama H, Yamaguchi K, Kozuka T, Takashima T, Seez P, Matsuura K. Adverse reactions to ionic and nonionic contrast media. A report from the Japanese Committee on the Safety of Contrast Media. Radiology. 1990;175:621-628.
22. Rodriguez RM, Gueant JL, Gastin IA, Angioi M, Abdelmoutaleb I, Saint-Laudy J, et al. Comparison of effects of ioxaglate versus iomeprol on histamine and tryptase release in patients with ischemic cardiomyopathy. Am J Cardiol. 2001;88:185-188.
23. Kanzaki T, Sakagami H. Late phase allergic reaction to a CT contrast medium (iotrolan). J Dermatol. 1991;18:528-531.
24. Spencer CM, Goa KL. Iodixanol. A review of its pharmacodynamic and pharmacokinetic properties and diagnostic use as an x-ray contrast medium. Drugs. 1996;52:899-927.
25. Salem DN, Findlay SR, Isner JM, Konstam MA, Cohen PF. Comparison of histamine release effects of ionic and non-ionic radiographic contrast media. Am J Med. 1986;80:382-384.
26. Lieberman P. The use of antihistamines in the prevention and treatment of anaphylaxis and anaphylactoid reactions. J Allergy Clin Immunol. 1990;86:684-686.
27. Laroche D, Namour F, Lefrancois C, Aimone-Gastin I, Romano A, Sainte-Laudy J, et al. Anaphylactoid and anaphylactic reactions to iodinated contrast material. Allergy. 1999;54 Suppl 58:13-16.
28. Sendo T, Itoh Y, Goromaru T, Sumimura T, Saito M, Aki K, et al. A potent tryptase inhibitor nafamostat mesilate dramatically suppressed pulmonary dysfunction induced by a radiographic contrast medium. Br J Pharmacol. 2003;138:959-967.
29. Ennis M, Lorenz W, Nehring E, Schneider C. In vitro and in vivo studies of radiographic contrast media-induced histamine release in pigs. Agents Actions. 1991;33:26-29.
30. 2+ and cyclic AMP in mast cell histamine release induced by radiographic contrast media. Naunyn Schmiedebergs Arch Pharmacol. 2003:367:364-371.
31. Stellato C, de Crescenzo G, Patella V, Mastronardi P, Mazzarella B, Marone G. Human basophil/mast cell releasability. XI. Heterogeneity of the effects of contrast media on mediator release. J Allergy Clin Immunol. 1996;97:838-850.
32. Peachell PT, Morcos SK. Effect of radiographic contrast media on histamine release from human mast cells and basophils. Br J Radiol. 1998;71:24-30.
33. Rudnick MR, Goldfarb S, Wexler L, Ludbrook PA, Murphy MJ, Halpern EF, et al. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The Iohexol Cooperative Study. Kidney Int. 1995;47:254-261.
34. Schwab SJ, Hlatky MA, Pieper KS, Davidson CJ, Morris KG, Skelton TN, et al. Contrast nephrotoxicity: a randomized controlled trial of a nonionic and an ionic radiographic contrast agent. N Engl J Med. 1989;320:149-153.
35. Lautin EM, Freeman NJ, Schoenfeld AH, Bakal CW, Haramati N, Friedman AC, et al. Radiocontrast-associated renal dysfunction: a comparison of lower-osmolality and conventional high-osmolality contrast media. Am J Roentgenol. 1991;157:59-65.
36. Barrett BJ, Parfrey PS, Vavasour HM, McDonald J, Kent G, Hefferton D, et al. Contrast nephropathy in patients with impaired renal function: high versus low osmolar media. Kidney Int. 1992;41:1274-1279.
37. Spinler SA, Goldfarb S. Nephrotoxicity of contrast media following cardiac angiography: pathogenesis, clinical course, and preventive measures, including the role of low-osmolality contrast media. Ann Pharmacother. 1992;26:56-64.
38. Barrett BJ, Carlisle EJ. Metaanalysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media. Radiology. 1993;188:171-178.
39. Aspelin P, Aubry P, Fransson SG, Strasser R, Willenbrock R, Berg KJ. Nephrotoxicity in High-Risk Patients Study of Iso-Osmolar and Low-Osmolar Non-Ionic Contrast Media Study Investigators: Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med. 2003;348:491-499.
40. Eisenberg RL, Bank WO, Hedgock MW. Renal failure after major angiography can be avoided with hydration. Am J Roentgenol. 1981;136:859-861.
41. Trivedi HS, Moore H, Nasr S, Aggarwal K, Agrawal A, Goel P, et al. A randomized prospective trial to assess the role of saline hydration on the development of contrast nephrotoxicity. Nephron Clin Pract. 2003;93:C29-C34.
42. Mueller C, Buerkle G, Buettner HJ, Petersen J, Perruchoud AP, Eriksson U, et al. Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med. 2002;162:329-336.
43. Merten GJ, Burgess WP, Gray LV, Holleman JH, Roush TS, Kowalchuk GJ, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA. 2004;291:2328-2334.
44. Moon SS, Back SE, Kurkus J, Nilsson-Ehle P. Hemodialysis for elimination of the nonionic contrast medium iohexol after angiography in patients with impaired renal function. Nephron. 1995;70:430-437.
45. Lehnert T, Keller E, Gondolf K, Schäffner T, Pavenstädt H, Schollmeyer P. Effect of haemodialysis after contrast medium administration in patients with renal insufficiency. Nephrol Dial Transplant. 1998;13:358-362.
46. Berger ED, Bader BD, Bosker J, Risler T, Erley CM. Contrast media-induced kidney failure cannot be prevented by hemodialysis. Dtsch Med Wochenschr. 2001;126:162-166.
47. Vogt B, Ferrari P, Schonholzer C, Marti HP, Mohaupt M, Wiederkehr M, et al. Prophylactic hemodialysis after radiocontrast media in patients with renal insufficiency is potentially harmful. Am J Med. 2001;111:692-698.
48. Huber W, Jeschke B, Kreymann B, Hennig M, Page M, Salmhofer H, et al. Haemodialysis for the prevention of contrast-induced nephropathy: outcome of 31 patients with severely impaired renal function, comparison with patients at similar risk and review. Invest Radiol. 2002;37:471-481.
49. Marenzi G, Marana I, Lauri G, Assanelli E, Grazi M, Campodonico J, et al. The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. N Engl J Med. 2003;349:1333-1340.
50. Gabutti L, Marone C, Monti M, Malfanti M, Zwahlen U, Pasotti E, et al. Does continuous venovenous hemodiafiltration concomitant with radiological procedures provide a significant and safe removal of the iodinated contrast ioversol? Blood Purif. 2003;21:152-157.
51. Liss P, Carlsson PO, Nygren A, Palm F, Hansell P. Et-A receptor antagonist BQ123 prevents radiocontrast media-induced renal medullary hypoxia. Acta Radiol. 2003;44:111-117.
52. Beach RE, Watts BA 3rd, Good DW, Benedict CR, DuBose TD Jr. Effects of graded oxygen tension on adenosine release by renal medullary and thick ascending limb suspensions. Kidney Int. 1991;39:836-842.
53. Ihle SL, Kostolich M. Acute renal failure associated with contrast medium administration in a dog. J Am Vet Med Assoc. 1991;199:899-901.
54. Heyman SN, Brezis M, Greenfeld Z, Rosen S. Protective role of furosemide and saline in radiocontrast-induced acute renal failure in the rat. Am J Kidney Dis. 1989;14:377-385.
55. Solomon R, Werner C, Mann D, D'Elia J, Silva P. Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med. 1994;331:1416-1420.
56. Stevens MA, McCullough PA, Tobin KJ, Speck JP, Westveer DC, Guido-Allen DA, et al. A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study. Prevention of Radiocontrast Induced Nephropathy Clinical Evaluation. J Am Coll Cardiol. 1999;33:403-411.
57. Hofbauer KG, Zschiedrich H, Gross F. Regulation of renin release and intrarenal formation of angiotensin. Studies in the isolated perfused rat kidney. Clin Exp Pharmacol Physiol. 1976;3:73-93.
58. Briggs JP, Schnermann J. Macula densa control of renin secretion and glomerular vascular tone: evidence for common cellular mechanisms. Ren Physiol. 1986;9:193-203.
59. Brooks DP. Role of endothelin in renal function and dysfunction. Clin Exp Pharmacol Physiol. 1996;23:345-348.
60. Karet FE, Kuc RE, Davenport AP. Novel ligands BQ123 and BQ3020 characterize endothelin receptor subtypes ETA and ETB in human kidney. Kidney Int. 1993;44:36-42.
61. Yamamoto T, Uemura H. Distribution of endothelin-B receptor-like immunoreactivity in rat brain, kidney, and pancreas. J Cardiovasc Pharmacol. 1998;31 Suppl 1:S207-S211.
62. Heyman SN, Clark BA, Kaiser N, Spokes K, Rosen S, Brezis M, et al. Radiocontrast agents induce endothelin release in vivo and in vitro. J Am Soc Nephrol. 1992;3:58-65.
63. Anarat A, Duman N, Noyan A, Kibar M, Anarat R. The role of endothelin in radiocontrast nephropathy. Int Urol Nephrol. 1997;29:609-613.
64. Margulies KB, Hildebrand FL, Heublein DM, Burnett JC Jr. Radiocontrast increases plasma and urinary endothelin. J Am Soc Nephrol. 1991;2:1041-1045.
65. Heyman SN, Clark BA, Cantley L, Spokes K, Rosen S, Brezis M, et al. Effects of ioversol versus iothalamate on endothelin release and radiocontrast nephropathy. Invest Radiol. 1993;28:313-318.
66. Brooks DP, DePalma PD. Blockade of radiocontrast-induced nephrotoxicity by the endothelin receptor antagonist, SB 209670. Nephron. 1996;72:629-636.
67. Pollock DM, Polakowski JS, Wegner CD, Opgenorth TJ. Beneficial effect of ETA receptor blockade in a rat model of radiocontrast-induced nephropathy. Ren Fail. 1997;19:753-761.
68. Bird JE, Giancarli MR, Megill JR, Durham SK. Effects of endothelin in radiocontrast-induced nephropathy in rats are mediated through endothelin-A receptors. J Am Soc Nephrol. 1996;7:1153-1157.
69. Clark BA, Kim D, Epstein FH. Endothelin and atrial natriuretic peptide levels following radiocontrast exposure in humans. Am J Kidney Dis. 1997;30:82-86.
70. Fujisaki K, Kubo M, Masuda K, Tokumoto M, Hirakawa M, Ikeda H, et al. Infusion of radiocontrast agents induces exaggerated release of urinary endothelin in patients with impaired renal function. Clin Exp Nephrol. 2003;7:279-283.
71. Wang A, Holcslaw T, Bashore TM, Freed MI, Miller D, Rudnick MR, et al. Exacerbation of radiocontrast nephrotoxicity by endothelin receptor antagonism. Kidney Int. 2000;57:1675-1680.
72. Erley CM, Heyne N, Burgert K, Langanke J, Risler T, Osswald H. Prevention of radiocontrast-induced nephropathy by adenosine antagonists in rats with chronic nitric oxide deficiency. J Am Soc Nephrol. 1997;8:1125-1132.
73. Katholi RE, Taylor GJ, McCann WP, Woods WT Jr, Womack KA, McCoy CD, et al. Nephrotoxicity from contrast media: attenuation with theophylline. Radiology. 1995;195:17-22.
74. Huber W, Ilgmann K, Page M, Hennig M, Schweigart U, Jeschke B, et al. Effect of theophylline on contrast material-nephropathy in patients with chronic renal insufficiency: controlled, randomized, double-blinded study. Radiology. 2002;223:772-729.
75. Jones BR, Bhalla RB, Mladek J, Kaleya RN, Gralla RJ, Alcock NW, et al. Comparison of methods of evaluating nephrotoxicity of cis-platinum. Clin Pharmacol Ther. 1980;27:557-562.
76. Erley CM, Duda SH, Rehfuss D, Scholtes B, Bock J, Muller C, et al. Prevention of radiocontrast-media-induced nephropathy in patients with pre-existing renal insufficiency by hydration in combination with the adenosine antagonist theophylline. Nephrol Dial Transplant. 1999;14:1146-1149.
77. Kramer BK, Preuner J, Ebenburger A, Kaiser M, Bergner U, Eilles C, et al. Lack of renoprotective effect of theophylline during aortocoronary bypass surgery. Nephrol Dial Transplant. 2002;17:910-915.
78. Shammas NW, Kapalis MJ, Harris M, McKinney D, Coyne EP. Aminophylline does not protect against radiocontrast nephropathy in patients undergoing percutaneous angiographic procedures. J Invasive Cardiol. 2001;13:738-740.
79. Murakami R, Machida M, Tajima H, Hayashi H, Uchiyama N, Kumazaki T. Plasma endothelin, nitric oxide and atrial natriuretic peptide levels in humans after abdominal angiography. Acta Radiol. 2002;43:340-343.
80. Rahman SN, Kim GE, Mathew AS, Goldberg CA, Allgren R, Schrier RW, et al. Effects of atrial natriuretic peptide in clinical acute renal failure. Kidney Int. 1994;45:1731-1738.
81. Weisberg LS, Kurnik PB, Kurnik BR. Risk of radiocontrast nephropathy in patients with and without diabetes mellitus. Kidney Int. 1994;45:259-265.
82. Kurnik BR, Allgren RL, Genter FC, Solomon RJ, Bates ER, Weisberg LS. Prospective study of atrial natriuretic peptide for the prevention of radiocontrast-induced nephropathy. Am J Kidney Dis. 1998;31:674-680.
83. Bakris GL, Lass NA, Glock D. Renal hemodynamics in radiocontrast medium-induced renal dysfunction: A role for dopamine-1 receptors. Kidney Int. 1999;56:206-210.
84. Madyoon H, Croushore L, Weaver D, Mathur V. Use of fenoldopam to prevent radiocontrast nephropathy in high-risk patients. Catheter Cardiovasc Interv. 2001;53:341-345.
85. Kini AS, Mitre CA, Kim M, Kamran M, Reich D, Sharma SK. A protocol for prevention of radiographic contrast nephropathy during percutaneous coronary intervention: effect of selective dopamine receptor agonist fenoldopam. Catheter Cardiovasc Interv. 2002;55:169-173.
86. Stone GW, McCullough PA, Tumlin JA, Lepor NE, Madyoon H, Murray P, et al. CONTRAST Investigators: Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. JAMA. 2003;290:2284-2291.
87. Allaqaband S, Tumuluri R, Malik AM, Gupta A, Volkert P, Shalev Y, et al. Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy. Catheter Cardiovasc Interv. 2002;57:279-283.
88. Wang YX, Jia YF, Chen KM, Morcos SK. Radiographic contrast media induced nephropathy: experimental observations and the protective effect of calcium channel blockers. Br J Radiol. 2001;74:1103-1108.
89. Duan SB, Liu FY, Luo JA, Wu HW, Liu RH, Peng YM, et al. Nephrotoxicity of high- and low-osmolar contrast media. The protective role of amlodipine in a rat model. Acta Radiol. 2000;41:503-507.
90. Neumayer HH, Junge W, Kufner A, Wenning A. Prevention of radiocontrast-media-induced nephrotoxicity by the calcium channel blocker nitrendipine: a prospective randomised clinical trial. Nephrol Dial Transplant. 1989;4:1030-1036.
91. Carraro M, Mancini W, Artero M, Stacul F, Grotto M, Cova M, et al. Dose effect of nitrendipine on urinary enzymes and microproteins following non-ionic radiocontrast administration. Nephrol Dial Transplant. 1996;11:444-448.
92. Spangberg-Viklund B, Berglund J, Nikonoff T, Nyberg P, Skau T, Larsson R. Does prophylactic treatment with felodipine, a calcium antagonist, prevent low-osmolar contrast-induced renal dysfunction in hydrated diabetic and nondiabetic patients with normal or moderately reduced renal function? Scand J Urol Nephrol. 1996;30:63-68.
93. Arici M, Usalan C, Altun B, Erdem Y, Yasavul U, Turgan C, et al. Radiocontrast-induced nephrotoxicity and urinary alpha-glutathione S-transferase levels: effect of amlodipine administration. Int Urol Nephrol. 2003;35:255-261.
94. Gurkowski L, MacDougall M, Wiegmann T. Effects of misoprostol on contrast-induced renal dysfunction. Am J Ther. 1995;2:837-842.
95. 1: a randomized, double-blind, placebo-controlled study. Am J Ther. 2001;8:155-162.
96. Paller MS, Hoidal JR, Ferris TF. Oxygen free radicals in ischemic acute renal failure in the rat. J Clin Invest. 1984;74:1156-1164.
97. Katholi RE, Woods WT Jr, Taylor GJ, Deitrick CL, Womack KA, Katholi CR, et al. Oxygen free radicals and contrast nephropathy. Am J Kidney Dis. 1998;32:64-71.
98. Birck R, Krzossok S, Markowetz F, Schnulle P, van der Woude FJ, Braun C. Acetylcysteine for prevention of contrast nephropathy: meta-analysis. Lancet. 2003;362:598-603.
99. Isenbarger DW, Kent SM, O'Malley PG. Meta-analysis of randomized clinical trials on the usefulness of acetylcysteine for prevention of contrast nephropathy. Am J Cardiol. 2003;92:1454-1458.
100. Alonso A, Lau J, Jaber BL, Weintraub A, Sarnak MJ. Prevention of radiocontrast nephropathy with N-acetylcysteine in patients with chronic kidney disease: a meta-analysis of randomized, controlled trials. Am J Kidney Dis. 2004;43:1-9.
101. Baker CS, Wragg A, Kumar S, De Palma R, Baker LR, Knight CJ. A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study. J Am Coll Cardiol. 2003;41:2114-2118.
102. Webb JG, Pate GE, Humphries KH, Buller CE, Shalansky S, Al Shamari A, et al. A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect. Am Heart J. 2004;148:422-429.
103. Miner SE, Dzavik V, Nguyen-Ho P, Richardson R, Mitchell J, Atchison D, et al. N-acetylcysteine reduces contrast-associated nephropathy but not clinical events during long-term follow-up. Am Heart J. 2004;148:690-695.
104. Emch TM, Haller NA. A randomized trial of prophylactic acetylcysteine and theophylline compared with placebo for the prevention of renal tubular vacuolization in rats after iohexol administration. Acad Radiol. 2003;10:514-519.
105. Heyman SN, Goldfarb M, Shina A, Karmeli F, Rosen S. N-acetylcysteine ameliorates renal microcirculation: studies in rats. Kidney Int. 2003;63:634-641.
106. Sehirli AO, Sener G, Satiroglu H, Ayanoglu-Dulger G. Protective effect of N-acetylcysteine on renal ischemia/reperfusion injury in the rat. J Nephrol. 2003;16:75-80.
107. Nowzari FB, Davidson SD, Eshghi M, Mallouh C, Tazaki H, Konno S. Adverse effects of oxidative stress on renal cells and its prevention by antioxidants. Mol Urol. 2000;4:15-19.
108. Liss P, Nygren A, Erikson U, Ulfendahl HR. Injection of low and iso-osmolar contrast medium decreases oxygen tension in the renal medulla. Kidney Int. 1998;53:698-702.
109. Drager LF, Andrade L, Barros de Toledo JF, Laurindo FR, Machado Cesar LA, Seguro AC. Renal effects of N-acetylcysteine in patients at risk for contrast nephropathy: decrease in oxidant stress-mediated renal tubular injury. Nephrol Dial Transplant. 2004;19:1803-1807.
110. Yano T, Itoh Y, Sendo T, Kubota T, Oishi R. Cyclic AMP reverses radiocontrast media-induced apoptosis in LLC-PK1 cells by activating A kinase/PI3 kinase. Kidney Int. 2003;64:2052-2063.
111. Zhang G, Gurtu V, Kain SR, Yan G. Early detection of apoptosis using a fluorescent conjugate of annexin V. Biotechniques. 1997;23:525-531.
112. Yano T, Itoh Y, Kubota T, Sendo T, Koyama T, Fujita T, et al. A prostacyclin analog prevents radiocontrast nephropathy via phosphorylation of cyclic AMP response element binding protein. Am J Pathol. In press
113. Xiang J, Chao DT, Korsmeyer SJ. BAX-induced cell death may not require interleukin 1b-converting enzyme-like proteases. Proc Natl Acad Sci USA. 1996;93:14559-14563.
114. Kroemer G. The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nature Med. 1997;3:614-620.
115. Gross A, Jockel J, Wei MC, Korsmeyer SJ. Enforced dimerization of BAX results in its translocation, mitochondrial dysfunction and apoptosis. EMBO J. 1998;17:3878-3885.
116. Robertson JD, Orrenius S. Role of mitochondria in toxic cell death. Toxicology. 2002;181-182:491-496.
117. Salvesen GS, Dixit VM. Caspases: intracellular signaling by proteolysis. Cell. 1997;91:443-446.
118. Thornberry NA, Lazebnik Y. Caspases: enemies within. Science. 1998;281:1312-1316.
119. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev. 1999;13:2905-2927.
120. Wilson BE, Mochon E, Boxer LM. Induction of Bcl-2 expression by phosphorylated CREB proteins during B-cell activation and rescue from apoptosis. Mol Cell Biol. 1996;16:5546-5556.
121. Ji L, Mochon E, Arcinas M, Boxer LM. CREB proteins function as positive regulators of the translocated bcl-2 allele in t(14;18) lymphomas. J Biol Chem. 1996;271:22687-22691.
122. Freeland K, Boxer LM, Latchman DS. The cyclic AMP response element in the Bcl-2 promoter confers inducibility by hypoxia in neuronal cells. Brain Res Mol Brain Res. 2001;92:98-106.
123. Pugazhenthi S, Nesterova A, Sable C, Heidenreich KA, Boxer LM, Heasley LE, et al. Akt/protein kinase B up-regulates Bcl-2 expression through cAMP-response element-binding protein. J Biol Chem. 2000;275:10761-10766.
124. Yano T, Itoh Y, Kubota T, Sendo T, Oishi R. A prostacyclin analog beraprost sodium attenuates radiocontrast media-induced LLC-PK1 cells injury. Kidney Int. 2004;65:1654-1663.
125. Boie Y, Rushmore TH, Darmon-Goodwin A, Grygorczyk R, Slipetz DM, Metters KM, et al. Cloning and expression of a cDNA for the human prostanoid IP receptor. J Biol Chem. 1994;269:12173-12178.
126. Komhoff M, Lesener B, Nakao K, Seyberth HW, Nusing RM. Localization of the prostacyclin receptor in human kidney. Kidney Int. 1998;54:1899-1908.
127. Villa E, Rabano A, Ruilope LM, Garcia-Robles R. Effects of cicaprost and fosinopril on the progression of rat diabetic nephropathy. Am J Hypertens. 1997;10:202-208.
128. Tobimatsu M, Ueda Y, Saito S, Tsumagari T, Konomi K. Effects of a stable prostacyclin analog on experimental ischemic acute renal failure. Ann Surg. 1998;208:65-70.
129. Paller MS, Manivel JC. Prostaglandins protect kidneys against ischemic and toxic injury by a cellular effect. Kidney Int. 1992;42:1345-1354.
130. Nielsen CB, Bech JN, Pedersen EB. Effects of prostacyclin on renal haemodynamics, renal tubular function and vasoactive hormones in healthy humans. A placebo-controlled dose-response study. Br J Clin Pharmacol. 1997;44:471-476.
131. Sim AK, McCraw AP, Cleland ME, Nishio S, Umetsu T. Effect of a stable prostacyclin analogue on platelet function and experimentally-induced thrombosis in the microcirculation. Arzneimittelforschung. 1985;35:1816-1818.
132. Kielpinska K, Walecki J, Giedrojc J, Turowska A, Kordecki K. Changes in the fibrinolytic system during angiography with ionic and with nonionic contrast media. Acad Radiol. 2002;9:283-289.
133. Van Beek EJ, Levi M, Reekers JA, Hack CE, Buller HR, ten Cate JW. Increased plasma levels of PAI-1 after administration of nonionic contrast medium in patients undergoing pulmonary angiography. Radiology. 1994;193:821-823.